Evaluation of Subcutaneous Proleukin (Interleukin-2) in a Randomized International Trial (ESPRIT): Geographical and Gender Differences in the Baseline Characteristics of Participants

REFERENCES

• Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295–1300.
   PubMed Web of Science ®Google Scholar
• Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication competent HIV despite prolonged suppression of plasma viraemia. Science. 1997;278:1291–1295.
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;53(5):696–699. Epub 2004 Mar 24.
   PubMed Web of Science ®Google Scholar
• John M, Nolan D, Melial S. Antiretroviral therapy and the lipodystrophy syndrome. Antiviral Ther. 2001;6: 9–20.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993–2003.
   PubMed Web of Science ®Google Scholar
• Nelson M, Matthews G, Brook MG, et al. BHIVA guidelines on HIV and chronic hepatitis: co-infection with HIV and hepatitis C virus infection (2005). HIV Med. 2005;6 (Suppl 2):96–106.
   PubMed Web of Science ®Google Scholar
• Yeni PG, Hammer SM, Hirsch MS, et al. Antiretroviral treat-ment for adult HIV infection. 2004 Recommendations of the International AIDS Society-USA panel. JAMA. 2004;292(2):251–265.
   PubMed Web of Science ®Google Scholar
• Davey RT, Chat RT, Piscitelli SC, et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type-1 infected persons. J Infect Dis. 1997;175:781–789.
   PubMed Web of Science ®Google Scholar
• Carr A, Emery S, Lloyd A, et al. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. J Infect Dis. 1998;178:992–999.
   PubMed Web of Science ®Google Scholar
• Levy Y, Capitant C, Houhou S, et al. Comparison of subcu-taneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet. 1999;353:1923–1929.
   PubMed Web of Science ®Google Scholar
• Davey RT, Chaitt D, Albert JM, et al. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpa-tient therapy for early human immunodeficiency virus type-1 infection. J Infect Dis. 1999;179:849–858.
   PubMed Web of Science ®Google Scholar
• Miller KD, Spooner K, Heroin BR, et al. Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4+ T-lymphocyte expansion. Clin lmmunol. 2001;99(1):30–42.
   PubMed Web of Science ®Google Scholar
• Davey RT, Murphy RL, Graziano FM, et al. Immunologic and virologic effects of subcutaneous interleukin-2 in com-bination with antiretroviral therapy: a randomised con-trolled trial. JAMA. 2000;284:183–189.
   PubMed Web of Science ®Google Scholar
• Abrams DI, Bebchuk JD, Denning ET, et al. Randomised, open-label study of the impact of two doses of subcutane-ous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cells counts 300/mm3: CPCRA 059. J AIDS. 2002;29:221–231.
   PubMed Web of Science ®Google Scholar
• Arduino RC, Nannini EC, Rodriguez-Barradas, et al. CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies. Clin Infect Dis. 2004;39(1):115–122. Epub 2004 Jun 14.
   PubMed Web of Science ®Google Scholar
• Natarajan V, Lempicki RA, Sereti I, et al. Increased periph-eral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection. PNAS. 2002;99(16):10712–10717.
   PubMed Web of Science ®Google Scholar
• Sereti I, Martinez-Wilson H, Metcalf JA, et al. Long-term effects of intermittent interleukin-2 therapy in patients with HIV infection: characterization of a novel subset of CD4+/ CD25+ T-cells. Blood. 2002;100(6):2159–2167.
   PubMed Web of Science ®Google Scholar
• Kovacs JA, Lempicki RA, Sidorov IA, et al. Induction of prolonged survival of CD4+ T-lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest. 2005;115:2139–2148.
   PubMed Web of Science ®Google Scholar
• Emery S, Capra WB, Cooper DA, et al. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis. 2000;182:428–434.
   PubMed Web of Science ®Google Scholar
• Emery S, Abrams DI, Cooper DA, et al. The evaluation of subcutaneous Proleukin (interleukin-2) in a randomised in-ternational trial: rational, design and methods of ESPRIT. Control Clin Trials. 2002 ;23(2):198–220.
   PubMedGoogle Scholar
• www.silcaat.org
   Google Scholar
• Tavel JA, Fosdick L, et al. Close out of four phase ll vanguard trials and patient roll-over into a large interna-tional phase III HIV clinical endpoint trial. Cont Clin Trials. 2001;22:42–48.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded sur-veillance case definition for AIDS among adolescents and adults. MMWR. 1992;41:1–20.
   Google Scholar
• Neaton JD, Wentworth DN, Rhame F, et al. Methods of studying interventions: considerations in choice of a clini-cal endpoint for AIDS clinical trials. Stat Med. 1994;13:2107–2125.
   PubMed Web of Science ®Google Scholar
• Gandhi MN, Ameli P, Bacchetti GB, et al. Eligibility criteria for HIV clinical trials and generalisability of results: the gap between published reports and study protocols. AIDS. In press.
   Web of Science ®Google Scholar
• www.fda.gov
   Google Scholar
• Egger, M, May M, Chene G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Lederberger B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observa-tional study. Lancet. 2003;362:22–29.
   PubMed Web of Science ®Google Scholar
• Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the Inter-national AIDS Society-USA Panel. JAMA. 2000;283(3):381–390.
   PubMed Web of Science ®Google Scholar
• Masur H, Kaplan JE, Holmes KK, U.S. Public Health Ser-vice, Infectious Diseases Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med. 2002;137(5 Pt 2):435–478.
   PubMed Web of Science ®Google Scholar